PL4347565T3 - Otrzymywanie związku inhibitora chk1 - Google Patents
Otrzymywanie związku inhibitora chk1Info
- Publication number
- PL4347565T3 PL4347565T3 PL22732474.6T PL22732474T PL4347565T3 PL 4347565 T3 PL4347565 T3 PL 4347565T3 PL 22732474 T PL22732474 T PL 22732474T PL 4347565 T3 PL4347565 T3 PL 4347565T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- inhibitor compound
- chk1 inhibitor
- chk1
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2107932.2A GB202107932D0 (en) | 2021-06-03 | 2021-06-03 | Preparation of a CHK1 Inhibitor Compound |
| PCT/EP2022/064903 WO2022253895A1 (en) | 2021-06-03 | 2022-06-01 | Preparation of a chk1 inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4347565T3 true PL4347565T3 (pl) | 2025-06-23 |
Family
ID=76838704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22732474.6T PL4347565T3 (pl) | 2021-06-03 | 2022-06-01 | Otrzymywanie związku inhibitora chk1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240287035A1 (pl) |
| EP (2) | EP4347565B1 (pl) |
| JP (1) | JP2024520724A (pl) |
| KR (1) | KR20240017056A (pl) |
| CN (1) | CN117529471A (pl) |
| AU (1) | AU2022286635A1 (pl) |
| BR (1) | BR112023025427A2 (pl) |
| CA (1) | CA3220991A1 (pl) |
| ES (1) | ES3025206T3 (pl) |
| GB (1) | GB202107932D0 (pl) |
| HU (1) | HUE071735T2 (pl) |
| IL (1) | IL308933A (pl) |
| MX (1) | MX2023014329A (pl) |
| PH (1) | PH12023553243A1 (pl) |
| PL (1) | PL4347565T3 (pl) |
| RS (1) | RS66790B1 (pl) |
| TW (1) | TW202310834A (pl) |
| WO (1) | WO2022253895A1 (pl) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| WO2003010444A1 (en) | 2001-07-23 | 2003-02-06 | Shock-Proof Solutions Pty Ltd | Mechanical shock absorbing apparatus |
| BRPI0412820A (pt) | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| MX2007000265A (es) | 2004-07-02 | 2007-07-20 | Icos Corp | Compuestos utiles para inhibir chk1. |
| EP1778648A2 (en) | 2004-08-19 | 2007-05-02 | ICOS Corporation | Compounds useful for inhibiting chk1 |
| PA8850801A1 (es) | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| US8785468B2 (en) * | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| GB0911042D0 (en) | 2009-06-25 | 2009-08-12 | Istituto Superiore Di Sanito | Treatment of tumorigenic cells in solid tumours |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| AR106772A1 (es) * | 2015-12-07 | 2018-02-14 | Lilly Co Eli | Sales de (s)-lactato |
| CN110678169A (zh) | 2017-03-31 | 2020-01-10 | 西雅图遗传学公司 | Chk1-抑制剂与weel-抑制剂的组合 |
-
2021
- 2021-06-03 GB GBGB2107932.2A patent/GB202107932D0/en not_active Ceased
-
2022
- 2022-06-01 RS RS20250464A patent/RS66790B1/sr unknown
- 2022-06-01 HU HUE22732474A patent/HUE071735T2/hu unknown
- 2022-06-01 AU AU2022286635A patent/AU2022286635A1/en active Pending
- 2022-06-01 EP EP22732474.6A patent/EP4347565B1/en active Active
- 2022-06-01 PH PH1/2023/553243A patent/PH12023553243A1/en unknown
- 2022-06-01 US US18/566,797 patent/US20240287035A1/en active Pending
- 2022-06-01 PL PL22732474.6T patent/PL4347565T3/pl unknown
- 2022-06-01 CN CN202280040052.4A patent/CN117529471A/zh active Pending
- 2022-06-01 ES ES22732474T patent/ES3025206T3/es active Active
- 2022-06-01 EP EP25158535.2A patent/EP4545516A1/en active Pending
- 2022-06-01 WO PCT/EP2022/064903 patent/WO2022253895A1/en not_active Ceased
- 2022-06-01 IL IL308933A patent/IL308933A/en unknown
- 2022-06-01 KR KR1020247000104A patent/KR20240017056A/ko active Pending
- 2022-06-01 JP JP2023574716A patent/JP2024520724A/ja active Pending
- 2022-06-01 MX MX2023014329A patent/MX2023014329A/es unknown
- 2022-06-01 CA CA3220991A patent/CA3220991A1/en active Pending
- 2022-06-01 BR BR112023025427A patent/BR112023025427A2/pt unknown
- 2022-06-02 TW TW111120729A patent/TW202310834A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3025206T3 (en) | 2025-06-06 |
| PH12023553243A1 (en) | 2024-03-25 |
| AU2022286635A1 (en) | 2023-12-21 |
| EP4347565A1 (en) | 2024-04-10 |
| IL308933A (en) | 2024-01-01 |
| EP4347565C0 (en) | 2025-04-02 |
| CN117529471A (zh) | 2024-02-06 |
| BR112023025427A2 (pt) | 2024-02-27 |
| EP4347565B1 (en) | 2025-04-02 |
| US20240287035A1 (en) | 2024-08-29 |
| TW202310834A (zh) | 2023-03-16 |
| JP2024520724A (ja) | 2024-05-24 |
| MX2023014329A (es) | 2024-02-06 |
| WO2022253895A1 (en) | 2022-12-08 |
| KR20240017056A (ko) | 2024-02-06 |
| RS66790B1 (sr) | 2025-06-30 |
| HUE071735T2 (hu) | 2025-09-28 |
| GB202107932D0 (en) | 2021-07-21 |
| CA3220991A1 (en) | 2022-12-08 |
| EP4545516A1 (en) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202209617B (en) | Crystalline hydrate of a jak inhibitor compound | |
| ZA202303655B (en) | Solid forms of a cdk4 inhibitor | |
| SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
| IL310234A (en) | Salts and solid-state configurations of a KIF18A inhibitory compound | |
| AU2021400317A9 (en) | Solid forms of a compound | |
| IL287630A (en) | Solid forms of glyt1 inhibitor | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| PL4157831T3 (pl) | Sposoby wytwarzania inhibitora jak1 | |
| IL304497A (en) | Crystalline forms of a pyrrolopyridine-aniline compound | |
| GB202004960D0 (en) | Inhibitor compounds | |
| HUE071735T2 (hu) | Chkl inhibitor vegyület elõállítása | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| GB202105879D0 (en) | A synthetic method of a cycloketone compound | |
| GB202005114D0 (en) | Crystalline Forms of a Pharmaceutical Compound | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| HK40125814A (en) | Preparation of a chk1 inhibitor compound | |
| GB2593902B (en) | Salt of a pharmaceutical compound | |
| IL319336A (en) | Pharmaceutical forms of CD73 inhibitor | |
| IL304683A (en) | Crystalline form of a piperazinyl-thiazole derivative | |
| SI4387730T1 (sl) | Trdne oblike rock inhibitorja | |
| IL304836A (en) | Polymorph of leterpyridine dihydrochloride | |
| GB2592622B (en) | Formulations of a dual aurora kinase/FLT3 inhibitor | |
| HK40099801A (en) | Solid forms of a compound | |
| GB202016708D0 (en) | Uses of chk2 inhibitors | |
| HK40086278A (en) | Crystalline forms of a tyk2 inhibitor |